102¦~7¤ë¸¹ ¹D ªk ªk °T (255)

DEEP & FAR

 

 

¬ü°ê³Ì°ªªk°|½s¸¹10-1150 
Mayo Collaborative Service, 
DBA Mayo Medical Laboratories, et al. 
v. Prometheus Laboratories Inc.

 

§d©É¬À ±M§Q¤@²Õ°Æ¥D¥ô

¡P ¥xÆW¤j¾Ç¶éÃÀ¾Ç¨t

¡P ¥xÆW¤j¾Ç´Óª«¬ì¾Ç¬ã¨s©Ò

 

 

½Ð¨D¶µ¦®¦bÀ³¥Î´y­z¦å²G¤¤¬Y¨Ç²¸áIËïÃþ¥NÁª«ªº¿@«×©MÃĪ«¾¯¶q±N·|µL®Ä©Î¾É­P¦³®`°Æ§@¥Îªº¥i¯à©Ê¤§¶¡ªºÃö«Yªº¦ÛµMªk«h¡C§Ú­Ì¥²¶·½T©w©Ò½Ð¨D¤èªk¬O§_±N³o¨Ç¤£¥i±M§Qªº¦ÛµMªk«hÂà¤Æ¬°¨º¨Çªk«hªº±M§Q¾A®æªºÀ³¥Î¡C§Ú­ÌÁ`µ²¡A¥L­Ì¨S¦³³o¼Ë°µ¡A¥B¦]¦¹¸Ó¤èªk¬O¤£¯à³Q±Â¤©±M§Qªº¡C

Ų©óªk°|ªº§P¨Ò¡A§Ú­Ìªºµ²½×¬O¥H§Ú­Ì¹ï©ó¯S©w½Ð¨D¶µªº¼f¬d¬°¨Ì¾Ú¡C¨º¨Ç®×¨Ò´£¿ô§Ú­Ì¡A¤£­n¥H¨Ï±M§Q¾A®æ©Ê¡§¶È¨ú¨M©ó°_¯ó¤HªºÃÀ³N¡¨¦Ó¨S¦³°Ñ·Ó¸T¤î¦ÛµMªk«hªº±M§Qªº­ì«hªº¤è¦¡¨Ó¸ÑÄÀ±M§Qªk³W¡CFlook, supra., at 593¡C¥L­Ì´£¿ô§Ú­Ì¤£­nÃÙ¦¨¨º¨Ç½Ð¨D¤Ó¼sªx¥ý¥e¨Ï¥Î¦ÛµMªk«hªº¤èªkªº±M§Q¡CMorse, supra., at 112-120¡FBenson, supra., at 71-72¡C¦Ó¥B¡A¥L­Ì°í«ù±Mª`¦b¦ÛµMªk«hªº¨Ï¥Îªº¤èªk¦pªG¥ç¥]§t¨ä¥L¤¸¯À©Î¤¸¯Àªº²Õ¦X¡A¦³®ÉºÙ¬°¡§¶i¨B©Ê·§©À(inventive concept)¡¨¡A¨ä¨¬¥H½T«O¸Ó±M§Q¹ê»Ú¤W­È±oª`¥Ø¦a²£¥Í¶W¹L¶È¨Ì¾Ú¦ÛµMªk«h¥»¨­ªº¤@­Ó±M§Qªº®ÄªG¡CFlook, supra., at 594¡F¥ç½Ð°Ñ¦ÒBilski, supra., at__(«D¥¿¦¡·N¨£(slip op.), at 14)(¡§¤£¯à³z¹L¸Õ¹Ï±N¤½¦¡ªº¨Ï¥Î­­©w©ó¯S©wªº§Þ³NÀô¹Ò©Î²K¥[µLÃöºò­nªº«áÄò¬¡°Ê¡]insignificant post-solution activity¡^¨Ó³WÁ×¹ï©ó©â¶H·§©À±Â¤©±M§Qªº¸T¤î¡C¤Þ¥ÎDiehr, supra, at 191-192)¡C

§Ú­Ì»{©w¨tª§¤èªk½Ð¨D¶µ¨S¦³º¡¨¬³o¨Ç±ø¥ó¡C¯S§O¬O¡A¦b©Ò½Ð¨D¤èªk¤¤ªº¨BÆJ(°£¤F¦ÛµMªk«h¥»¨­¥H¥~)²o¯A¥ý«e¥»»â°ì¬ã¨s¤H­û©Ò±q¨Æªº¼ôª¾¡B±`³W¥B¶Ç²Îªº¬¡°Ê¡C

 

 

¡]«ÝÄò¡^